Gain Therapeutics’ (GANX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Gain Therapeutics (NASDAQ:GANX) in a research report report published on Monday, Marketbeat.com reports. They currently have a $8.00 price objective on the stock. HC Wainwright also issued estimates for Gain Therapeutics’ Q4 2026 earnings at ($0.12) EPS, FY2026 earnings at ($0.49) EPS, Q1 2027 earnings at ($0.13) EPS, Q2 2027 earnings at ($0.13) EPS and FY2027 earnings at ($0.49) EPS.

Several other equities research analysts have also recently commented on GANX. Roth Capital reaffirmed a “buy” rating on shares of Gain Therapeutics in a research note on Tuesday, May 12th. Wall Street Zen raised Gain Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, June 21st. Oppenheimer restated an “outperform” rating on shares of Gain Therapeutics in a report on Wednesday, May 27th. BTIG Research reaffirmed a “buy” rating and set a $5.00 price objective on shares of Gain Therapeutics in a research report on Tuesday, August 11th. Finally, Weiss Ratings lowered shares of Gain Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 9th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Gain Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $7.50.

Gain Therapeutics Stock Performance

Shares of Gain Therapeutics stock opened at $1.79 on Monday. The company has a current ratio of 4.36, a quick ratio of 4.36 and a debt-to-equity ratio of 0.02. The business has a 50-day moving average price of $1.85 and a two-hundred day moving average price of $1.94. Gain Therapeutics has a 1-year low of $1.53 and a 1-year high of $4.34. The company has a market cap of $78.12 million, a P/E ratio of -3.58 and a beta of 0.20.

Gain Therapeutics (NASDAQ:GANX) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.03. As a group, analysts anticipate that Gain Therapeutics will post -0.5 EPS for the current year.

Institutional Trading of Gain Therapeutics

Large investors have recently made changes to their positions in the company. HighTower Advisors LLC acquired a new position in Gain Therapeutics during the 2nd quarter worth approximately $35,000. HB Wealth Management LLC bought a new position in Gain Therapeutics in the second quarter worth approximately $26,000. Two Sigma Securities LLC acquired a new stake in Gain Therapeutics in the second quarter valued at approximately $26,000. BlackRock Inc. acquired a new stake in Gain Therapeutics in the second quarter valued at approximately $558,000. Finally, GSA Capital Partners LLP bought a new stake in shares of Gain Therapeutics during the second quarter valued at approximately $1,283,000. 11.97% of the stock is currently owned by institutional investors and hedge funds.

About Gain Therapeutics

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.